0001564590-17-006893.txt : 20170615 0001564590-17-006893.hdr.sgml : 20170615 20170421171455 ACCESSION NUMBER: 0001564590-17-006893 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTORI THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001095981 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330827593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 3020 CALLAN ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584580900 MAIL ADDRESS: STREET 1: 3020 CALLAN ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: MACROPORE INC DATE OF NAME CHANGE: 20010320 CORRESP 1 filename1.htm cytx-corresp.htm

 

 

 

Cytori Therapeutics, Inc.

3020 Callan Road

San Diego, CA 92121

 

 

 

April 21, 2017

 

VIA EDGAR

 

Amanda Ravitz

Assistant Director

Office of Electronics and Machinery

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Cytori Therapeutics, Inc.

Registration Statement on Form S-3

Filed March 27, 2017

File No. 333-216947

 

Dear Ms. Ravitz:

 

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Cytori Therapeutics, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:30 P.M. Eastern Time on April 25, 2017, or as soon as practicable thereafter.

 

The undersigned, on behalf of the Company, acknowledges the following:

 

 

•

should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

 

•

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

 

•

the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 

If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435.  Thank you for your assistance and cooperation in this matter.

 

Very truly yours,

 

CYTORI THERAPEUTICS, INC.

 

 

 

                                                                 By:  _/s/ Tiago M. Girão______

       Tiago M. Girão    Chief Financial Officer

 

 

 

cc:Cheston J. Larson, Esq., Latham & Watkins LLP